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Abstract 
Background: Prenatal maternal lipopolysaccharide (LPS) exposure leads to behavioral deficits such as depression, 
anxiety, and schizophrenia in the adult lives. LPS‑exposure resulted in the production of cytokines and oxidative dam‑
age. On the contrary, astaxanthin is a carotenoid compound, showed neuroprotective properties via its antioxidant 
capacity. This study examines the effect of astaxanthin on the prenatal maternal LPS‑induced postnatal behavioral 
deficit in mice.
Results: We found that prenatal LPS‑exposed mice showed extensive immobile phase in the tail suspension test, 
higher frequent head dipping in the hole‑board test and greater hypolocomotion in the open field test. All these val‑
ues were statistically significant (p < 0.05). In addition, a marked elevation of the level of lipid peroxidation, advanced 
protein oxidation product, nitric oxide, while a pronounced depletion of antioxidant enzymes (superoxide dismutase, 
catalase and glutathione) were observed in the adult offspring mice that were prenatally exposed to LPS. To the con‑
trary, 6‑weeks long treatment with astaxanthin significantly improved all behavioral deficits (p < 0.05) and diminished 
prenatal LPS‑induced oxidative stress markers in the brain and liver.
Conclusions: Taken together, these results suggest that prenatal maternal LPS‑exposure leads to behavioral deficits 
in the adults, while astaxanthin ameliorates the behavioral deficits presumably via its antioxidant property.
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Background
Administration of lipopolysaccharide (LPS) into preg-
nant rodents strongly impaired innate immune responses 
[1] without the presence of infection [2]. LPS has been 
widely used in rodents during pregnancy to study 
behavioral deficits and histological irregularities in the 
adult offspring [3–6]. Prenatal maternal LPS challenge 
increases pro-inflammatory cytokines that cross the 
placental barrier and interfere with the early stages of 
brain development. The developmental abnormality is 
expressed in the behavioral level during the adult stage 
of life. Human epidemiological data suggests, early infec-
tions can produce mental disorders [7].
Prenatal LPS-induced maternal immune activation 
model has been used to develop animal model of depres-
sion [8], anxiety [9–11], impairment in learning and 
memory [12, 13], schizophrenia [14–16] and autism [17, 
18]. In addition, prenatal LPS-exposure is linked with the 
development of long-term physiological complications 
in the offspring animals [19]. During gestational period, 
a specific time window is critical in inducing neurode-
velopmental disorder and impaired behavioral deficits in 
the rodent’s offspring [6]. In this window, LPS-exposure 
leads to produce cytokines that crosses the placental bar-
rier, which in turn interrupts the processes of fetal brain 
development [20]. Prenatal LPS-exposure has shown to 
enhance the level of nitric oxide (NO), lipid peroxidation 
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and depleted the level of glutathione in the maternal liver, 
embryo, and placenta [21]. LPS-induced intrauterine fetal 
death and growth restriction are associated with higher 
lipid peroxidation and glutathione depletion in maternal 
liver, placenta, and fetal liver [22]. Cytokine independent 
reactive oxygen species (ROS) production has also been 
reported even within 40  min after LPS stimulation to 
human umbilical vein endothelial cells [23].
Based on the current data, it is hypothesized that pre-
natal LPS administration may contribute to adult behav-
ioral dysfunction. It is also thought that ROS might play 
a significant role in the progression of such dysfunction. 
We assume that antioxidant like astaxanthin may scav-
enge oxidative stress in the brain to improve the impaired 
brain function. Therefore, this study investigates- (i) the 
effect of prenatal maternal LPS-exposed behavioral dis-
orders and oxidative damage in the adult offspring and 
(ii) the effect of a potential antioxidant (astaxanthin) 
treatment in this prenatal LPS-exposed model.
Previous study used LPS at various dose range includ-
ing small (120  µg/kg, i.p.) at GD 15–17 [24], moderate 
(300 µg/kg, i.p.) at GD 16–17 [12] to high (800 µg/kg, i.p.) 
at GD 15–17 [25] in mice model of behavioral deficit. In 
this study, moderate dose of LPS (300 µg/kg, body weight) 
was selected for Swiss albino mice. On the contrary, astax-
anthin (AST) is a carotenoid antioxidant, having 100–500 
times greater antioxidant capacity than α-tocopherol [26]. 
The BBB crossing ability of AST was evident, and pos-
sess neuroprotective properties [27] by the restoration of 
antioxidant enzymes such as, superoxide dismutase and 
glutathione peroxidase, and reduction of lipid peroxida-
tion (MDA) [28], down-regulation of increased nuclear 
factor-kappaB (NF-kB), and expression of inflamma-
tory cytokines [29]. Moreover, astaxanthin treatment 
improves depressive-like behavior by reducing the level of 
IL-6 and IL-β in the frontal cortex [30]. AST has shown a 
dose-dependent anti-inflammatory effect, by suppressing 
NO, and tumor necrosis factor- α (TNF-α) production, 
through directly blocking nitric oxide synthase enzyme 
activity. It is hypothesized that AST might be an effective 
antioxidant treatment of choice to improve LPS-exposed 
oxidative stress in adult lives.
Methods
Animals
Adult (age: 6 months) female (n = 12) Swiss albino mice 
(weight: 30 ±  2  g) were used for this experiment. Ani-
mals were housed in animal cage (Tecniplast, Italy) at 
21 ± 2 °C room temperature, relative humidity 55 ± 5 % 
and 12-h light/dark cycle; and feed pellets and water 
ad libitum. Females with vaginal plug were designated as 
on embryonic day (ED) 0. The experimental procedure 
was reviewed and approved by the institutional ethical 
committee at the Department of Pharmaceutical Sci-
ences, North South University (NSU/PHA/2014/133-
046), Dhaka, Bangladesh. Animals were handled in 
accordance with the international principles guiding 
the usage and handling of experimental animals (United 
States National Institute for Health Publication, 1985). 
Behavioral and neuroendocrine parameters might be 
influenced by different estrous cycle phases [31]. There-
fore, estrous cycle in female offspring was monitored 
before deciding the day for behavioral test.
Animal grouping
Female pregnant mice were divided into two groups at 
ED 16 and ED 17. Control_saline group (n = 6) received 
intraperitoneal water for injection (100  µl) (Fig.  1) and 
experimental group (n  =  6) received intraperitoneal 
LPS (Escherichia coli, Sigma-Aldrich, USA) at a dose of 
300 µg/kg, body weight. Forty pups were selected for the 
postnatal experiments. On postnatal day 23 offspring 
were weaned and separated based on the gender. Off-
spring male animals were randomly selected and further 
grouped into four on postnatal day (PD) 90 as- (i) con-
trol_saline (n = 10), (ii) control_AST (n = 10), (iii) LPS 
(n = 10) and (iv) LPS_AST (n = 10).
Control mice received either oral saline (100 μl) or oral 
astaxanthin (2 mg/kg, body weight; while LPS group was 
exposed to prenatal LPS and later received either oral 
saline (100 μl) or oral astaxanthin (2 mg/kg, body weight 
for 6 weeks). Behavioral test was conducted within 3 days 
(PD 133, 134 and 135) in the order of open field test fol-
lowed by tail suspension and hole-board test. Within this 
period we have not seen any estrous cycle that may affect 
our behavioral results. Earlier, we decided to extend the 
treatment period (astaxanthin) if estrous cycle would 
appear. At the end of the behavioral test, animals were 
sacrificed to collect tissue.
Preparation of astaxanthin and lipopolysaccharide
LPS (300  μg/kg) from E. coli, Sigma Aldrich, USA was 
dissolved in sterile water for injection [32] while water for 
injection (100 μL) was purchased from pharmacy shops. 
Astaxanthin powder was received as a gift from Pharma 
raw Bangladesh. AST was dissolved in distilled water at 
a concentration of 600 μg/ml and administered orally at 
a dose of 2 mg/kg body weight; [33] for 6 weeks starting 
from PD 91 to PD132.
Behavioral test
Open field test
The open field test device was made of plastic wood mate-
rial following measurements described earlier [34]. The 
light source was a 35  w bulb suspended approximately 
1  m above the apparatus for background lighting. Mice 
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were carried to the testing room in their home cages and 
handled by the tails and were placed in the apparatus and 
allowed to explore the field for 20 min. After each trail, 
apparatus was cleaned using 70  % ethanol and allowed 
to dry. The exploration was recorded for later analysis 
by using a Logitech™ 4mp webcam. Video was analyzed 
manually using Smart™ V 3.0 video tracking software 
developed by PanLab. During the analysis, center zone 
and periphery zone were defined where center zone con-
sists of 34.5 × 34.5 cm.
Hole‑boardtest
Hole-board test device box was constructed using plas-
tic wood (length: 42  cm, width: 42  cm, height: 30  cm) 
containing twenty holes (4 cm diameter) in the floor. We 
considered gross exploratory behavior as the number of 
head dips into the holes (placing the head or snout into 
the holes in the floor). Video camera was installed to 
record the frequency and duration of each dipping. Loco-
motion-related behavior was scored as the number of 
rearings. The hole-board was cleaned between sessions.
Tail suspension test
Tail suspension test (TST) was conducted according 
to the previous procedure described [35]. Briefly, each 
mouse was suspended by its tail using a clamp, 2  cm 
from the distal end, for 5 min in a gray plastic box (40 cm 
high, 30 cm wide, and 20 cm deep), with the head about 
above the floor (60 cm). Duration of immobility (defined 
as the absence of all movement except for those required 
for respiration) and mobility time were recorded (in sec-
onds) for 5 min. Animals that climbed their tails during 
TST were excluded. Mobility was termed as hind leg 
movement, while immobility was defined as the absence 
of whole-body movement.
Tissue processing
Brain and liver tissues were processed according to our 
previous method [36]. Mice were anesthetized with 
0.1 ml of ketamine (50 mg/ml) and perfused through the 
heart with cold 0.9 % NaCl and phosphate buffered saline 
(PBS) to remove blood from the brain and liver tissue. 
The whole brain was immediately removed and kept in a 
petridish containing saline on ice. Cortex (100 mg) regions 
from the brain and liver (100  mg) tissues were collected 
to prepare 10  % (w/v) homogenate in sodium phosphate 
buffer (30 mmol/l, pH 7.0) using Ultra-Turrax T25 (USA) 
homogenizer. Homogenized tissue samples were sonicated 
at 5 s cycle for 150 s using an ultrasonic processor.
Oxidative stress estimation
Lipid peroxidation (MDA)
Lipid peroxidation was estimated colorimetrically meas-
uring thiobarbituric acid reactive substances (TBARS) 
Fig. 1 Grouping of the experimental animals. Effects of astaxanthin treatment on the adult mice prenatally exposed to either LPS or saline (control). 
Swiss albino mice were either treated withwater for injection (100 µl, saline, n = 6) or LPS (300 µg/kg, body weight) via intraperitoneal route at ED 
16 and ED 17. Offspring male animals were randomly selected and further grouped into four on postnatal day (PD) 90 as‑ (i) control_saline (100 μl 
saline, n = 10), (ii) control_AST (astaxanthin, n = 10), (iii) LPS (100 μl saline,n = 10) and (iv) LPS_AST (astaxanthin,n = 10). The treatment was given 
for 6 weeks (PD 91–132). On PD 133 open field test was conducted followed by tail suspension and hole‑board test. At the end of the behavioral 
test, animals were sacrificed to collect tissue
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as described previously [37]. Briefly, tissue homogen-
ate (0.1  ml +Tris–HCl buffer, pH 7.5) was treated with 
2 ml of (1:1:1 ratio) TBA-TCA-HCl reagent (thiobarbitu-
ric acid 0.37  %, 0.25  N HCl and 15  % TCA) and placed 
in water bath for 30 min and cooled. The absorbance of 
clear supernatant was measured against reference blank 
at 535 nm.
Catalase (CAT)
Activity of catalase (CAT) enzyme was assayed at 240 nm 
and expressed as activity in percentage of H2O2 con-
sumed/min/mg protein as described [38]. The reaction 
mixture (1.5  ml) contained phosphate buffer (1.0  ml) 
(0.01 M, pH 7.0), tissue homogenate (0.1 ml supernatant) 
and H2O2 (0.4 ml) (2 M). The reaction was stopped by the 
addition of 2.0 ml of dichromate-acetic acid reagent (5 % 
potassium dichromate and glacial acetic acid were mixed 
in 1:3 ratio).
Nitric oxide (NO)
Nitric oxide was determined according to the method 
described by Tracy et  al. as nitrate and nitrite [39]. 
NO level was measured by using standard curve and 
expressed as nmol/gm of tissue. Griess-Illosvoy reagent 
was modified by using naphthyl ethylene diaminedi-
hydrochloride (NED) (0.1  % w/v) instead of 1-napthyl-
amine (5 %). The reaction mixture (3 ml) containing brain 
homogenates (0.5  ml), phosphate buffer saline (0.5  ml), 
NED (1  ml) and sulfanilamide (1  ml) was incubated at 
25 °C for 15 min. A pink chromophore was formed in dif-
fused light. The absorbance of the solution was measured 
at 540 nm against the corresponding blank solution.
Advanced protein oxidation product (APOP)
Advanced protein oxidation product was assayed based 
on spectrophotometric detection according to [40]. 
APOPs were expressed in chloramine units (nmol/ml). 
Briefly, plasma (50  µl diluted with phosphate-buffered 
saline (PBS) (100  µl), and chloramin T (0–100  mmol/l) 
were used for the preparation of calibration curve and 
PBS was used as blank. Potassium iodide (100  µl of 
1.16 M) and acetic acid (50 µl) were added to each well 
and absorbance was taken at 340 nm immediately.
Superoxide dismutase (SOD)
The activity of superoxide dismutase enzyme was assayed 
by a modified procedure described previously [41]. 
Briefly, each 300  μl reaction mixture contained 50  mM 
sodium phosphate (pH 7.8), 13 mM methionine, 75 mM 
nitrobluetetrazolium (NBT), 2  mM riboflavin, 100  mM 
EDTA, and 2 ml of plasma. The change of absorbance in 
each sample was then recorded at 560 nm after the pro-
duction of blue formazan.
Glutathione (GSH)
Glutathione in the brain was assayed according to the 
previous method [42]. Briefly, 1 ml of plasma was added 
with 2.7  ml of phosphate buffer (0.1  mol/l, pH 8) and 
0.2 ml of 5, 5-dithio-bis (2-nitrobenzoic acid). The color 
developed was measured immediately at 412 nm. Results 
are expressed as μmol/mg protein.
Statistics
The data of this present study was analyzed by one-way 
ANOVA to compare the main effect of astaxanthin on 
dependent variables in control_saline, control_AST, 
LPS, and LPS_AST groups. Post-hoc test namely “New-
man-Keuls” was used as a multiple comparisons test to 
compare between groups. All analyses were carried out 
using GraphPad Prism software (version 6.0). The differ-
ences were considered significant when p values were at 
least less than 0.05. Data are represented as mean ± SEM 




A significant main effect of treatment on the number of 
entry into the periphery [F(3,36) = 6.34, p < 0.01] (Fig. 2a), 
time spent in periphery [F(3,33) = 6.95, p < 0.001] (Fig. 2b) 
and total distance travelled [F(3,34)  =  4.49, p  <  0.01] 
(Fig. 2c) was observed for four conditions (control_saline, 
LPS, LPS_AST, control_AST). Neuman-keuls multiple 
comparison test showed that control_saline (M = 29.50, 
SD  =  10.33), LPS_AST (M  =  32.70, SD  =  15.09) and 
control_AST (M  =  44.50, SD  =  18.45) groups had 
lower entry frequency in the periphery than LPS group 
(M = 63.10, SD = 27.99). Similarly LPS group (M = 949, 
SD  =  147) spent longer time in periphery than con-
trol_saline (M =  695, SD =  167), LPS_AST (M =  804, 
SD = 141) and control_AST (M = 678, SD = 126) groups. 
Moreover, LPS group (M = 213, SD = 46) travelled lower 
distance than control_saline (M =  320, SD =  96), LPS_
AST (M =  328, SD =  36) and control_AST (M =  301, 
SD = 133) groups.
Tail suspension test
There was a significant main effect of treatment on the 
duration of immobile time [F(3,34) = 7.39, p < 0.001], and 
mobile time [F(3,35) =  4.17, p  <  0.01] for the four condi-
tions (control_saline, LPS, LPS_AST, control_AST). 
Neurman-keuls multiple comparison test showed that 
control_saline (M = 179, SD = 47), LPS_AST (M = 172, 
SD = 67) and control_AST (M = 219, SD = 47) groups 
had lower immobile phase than LPS group (M  =  269, 
SD  =  39) (Fig.  3a). Likewise, control_saline (M  =  167, 
SD =  43) and LPS_AST (M =  154, SD =  66) spent less 
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mobile phase than LPS group (M = 91, SD = 39) (Fig. 3b). 
However, control_AST (M = 125, SD = 52) group did not 
show significant difference from any other groups.
Hole‑board test
There was a significant main effect of head dipping fre-
quency [F(3,34)  =  8.69, p  <  0.001] (Fig.  3c) and head 
dipping duration [F(3,36) = 9.86, p < 0.001] (Fig. 3d). Neu-
rman-keuls multiple comparison test showed that con-
trol_saline (M =  43.0, SD =  6.5), LPS_AST (M =  46.3, 
SD = 4.3) and control_AST (M = 52.6, SD = 8.1) groups 
had lower frequency of head dipping than LPS group 
(M  =  65.0, SD  =  16.8). Additionally, control_saline 
(M = 81.8, SD = 27.2), LPS_AST (M = 76.7, SD = 20.1) 
and control_AST (M  =  84.4, SD  =  18.6) groups 
spent lower duration of head dipping than LPS group 
(M = 125.0, SD = 22.6).
Oxidative stress
One-way ANOVA analysis showed a significant 
main effect of treatment on the MDA level in brain 
[F(3,36) = 6.19, p < 0.01] (Fig. 4a), and liver [F(3,35) = 4.37, 
p  <  0.01] (Fig.  4b); AOPP in the brain [F(3,34)  =  5.27, 
p = 0.01] (Fig. 4c), and liver [F(3,34) = 18.06, p = 0.001] 
(Fig.  4d); NO in the brain [F(3,33)  =  40.47, p  <  0.001] 
(Fig. 4e) and liver [F(3,31) = 28.39, p < 0.001] (Fig. 4f ); glu-
tathione in the brain [F(3,36) = 266.1, p < 0.001] (Fig. 4g) 
and liver [F(3,35)  =  16.79, p  <  0.001] (Fig.  4h); catalase 
activity in the brain [F(3,34) = 9.45, p < 0.001] (Fig. 4i) and 
liver [F(3,36) = 16.27, p < 0.001] (Fig. 4j); and SOD activity 
in the brain [F(3,34) = 6.97, p < 0.001] (Fig. 4k) and liver 
[F(3,32) =  9.75, p < 0.001] (Fig. 4l) among the four treat-
ment groups.
Neurman-keuls multiple comparison test indicated 
a lower level of MDA in the control_saline (M  =  27.0, 
SD = 8.5), LPS_AST (M = 32.7, SD = 8.3) and control_
AST (M = 29.5, SD = 4.3) groups than LPS (M = 40.7, 
SD  =  8.7) in the brain. Similar findings were observed 
in liver MDA also. Likewise, lower level of AOPP was 
found in control_saline (M = 80.0, SD = 25.0), LPS_AST 
(M  =  82.1, SD  =  26.1) and control_AST (M  =  40.3, 
SD = 3.5) than LPS (M = 121.6, SD = 12.3) in the brain. 
Similar findings were again observed in liver AOPP. 
In addition, control_saline (M  =  3.2, SD  =  2.1), LPS_
AST (M  =  8.3, SD  =  1.9) and control_AST (M  =  2.4, 
SD  =  1.6) groups had lower NO than LPS (M  =  11.2, 
SD = 2.2) in the brain. Similar results were observed in 
liver NO as well.
To the contrary, control_saline (M =  11.7, SD =  1.7), 
LPS_AST (M  =  3.5, SD  =  0.5) and control_AST 
Fig. 2 Effects of astaxanthin on locomotor activity in the open field test (OFT).The parameters of interest in the open field test are number of entry 
in periphery (a); time spent in periphery (b); and total distance travelled (c).Results were shown as mean ± SEM. *p < 0.05, **p < 0.01
Fig. 3 Effects of astaxanthin on immobility and mobility time in the tail suspension test (TST) and hole‑board test in LPS‑exposed mice. Results 
are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. Tail suspension test parameters are duration of immobility time (a) and duration of 
mobility time (b) while hole‑board test parameters are frequency (c) and duration of head dipping (d)
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(M = 16.2, SD = 1.7) groups had higher GSH than LPS 
(M = 1.2, SD = 0.6) in the brain. Interestingly, data from 
liver showed different result. Control_saline (M  =  4.0, 
SD = 0.8) and LPS_AST (M = 3.2, SD = 1.0) had higher 
GSH than LPS (M  =  2.2, SD  =  0.5) and control_AST 
(M  =  1.6, SD  =  0.2). The level of CAT in the con-
trol_saline (M =  12.3, SD =  3.6), LPS_AST (M =  11.9, 
SD =  4.1) and control_AST (M =  16.4, SD =  1.5) was 
higher than LPS (M = 8.3, SD = 2.3) in the brain. Simi-
lar findings were further observed in liver CAT. SOD data 
revealed that control_saline (M = 21.4, SD = 6.5), LPS_
AST (M = 21.5, SD = 5.9) and control_AST (M = 25.0, 
SD = 2.7) groups had higher SOD than LPS (M = 14.4, 
SD =  2.6) in the brain. Liver SOD levels were similarly 
consistent with that of the brain.
Discussion
The result of the present study demonstrated that; pre-
natal LPS-exposure leads to anxiety and depressive like 
behaviors, and oxidative damage in the brain and liver 
during the adult lives. To the contrary, postnatal treat-
ment with astaxanthin ameliorates impaired behavior 
and oxidative markers in the prenatal LPS-exposed off-
spring mice.
It has been demonstrated that prenatal maternal 
immune activation with LPS elicits behavioral deficits 
such as reduced locomotoractivity [9, 43] and social 
exploration [44] in the open field test in the adult lives 
[9]. In this study, prenatal maternal LPS-exposed ani-
mals have shown an increased time in the peripheral 
region and reduced global activity in the open field test. 
In addition, prenatal LPS-exposed animals have spent 
an increased immobility and reduced mobility time 
in the tail suspension test in the offspring. These indi-
cate the development of behavioral deficits in the adult 
offspring of LPS group. Increased duration of immobil-
ity in the tail suspension test was also observed in the 
prenatally stressed rats [45] and mice [46]. To be noted 
that, when astaxanthin was given to healthy animals, it 
further showed similar effects as produced by prenatal 
LPS. This may be explained as the adverse effect of any 
potent drug/chemical when given at normal physiology. 
When the immunity was challenged by prenatal LPS, 
the therapeutic effect of astaxanthin became noticeable. 
It is important to note that, 6-weeks-long treatment 
with astaxanthin improves the parameters of open field 
and tail suspension test in the offspring animals. Ying 
et  al. (2015) has shown that 10  weeks treatment with 
Fig. 4 Effects of astaxanthin on the oxidative markers in the brain and liver in prenatally LPS‑exposed animals. Oxidative stress parameters are lipid 
peroxidation (MDA) in the brain (a) and liver (b); advanced oxidation of protein products (AOPP) in the brain (c) and liver (d); nitric oxide (NO) in the 
brain (e) and liver (f); glutathione (GSH) in the brain (g) and liver (h); catalase (CAT) in the brain (i) and liver (j); and superoxide dismutase (SOD) in the 
brain (k) and liver (l). Results are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001
Page 7 of 10Al‑Amin et al. BMC Neurosci  (2016) 17:11 
astaxanthin (25 mg/kg/day, body weight) increases loco-
motor activity by enhancing total travelling distance in 
the open field test [30].
Our results demonstrated that prenatal maternal LPS 
exposure leads to increased anxiety in the adult offspring 
as evident in the hole-board test. Our results are con-
sistent with previous studies demonstrating that prena-
tal LPS-exposure in the late gestational stage resulted in 
increased anxiety and depressed behaviors in the adult 
mice. Prenatal LPS-exposed mice exhibited a higher level 
of anxiety as evident even in the postnatal day 240 [47]. 
To the contrary, treatment with astaxanthin reverses anx-
iety-like disorder in the mice. Our results are in line with 
the other studies [48, 49].
Our results depict that prenatally LPS-exposed ani-
mals had decreased levels of antioxidant enzymes such 
as, superoxide dismutase, catalase and glutathione, while 
an increased level of lipid peroxidation, protein oxidation 
products, and NO in the adult lives. These results indi-
cated the correlation of prenatal administration of LPS 
with the oxidative stress in the adult lives. The depletion 
of antioxidant enzymes have shown by the other studies. 
For example, LPS-induced depletion of endogenous anti-
oxidant enzymes including superoxide dismutase, cata-
lase has been reported earlier [50].
LPS-induced lipid peroxidation has been shown in 
in  vitro [51–53] and in  vivo [54] animal studies. It has 
been revealed that LPS-exposure results in neurotoxicity 
via microglial activation. In-utero LPS-induction causes 
the activation of microglia. This activated microglia pro-
duces increased level of NO, ROS, and inflammatory 
cytokines such as TNF-α [55]. Activated microglia and 
astrocyte cells accelerate iNOS induction which results in 
the production of ROS. NO may harm oligodendrocytes 
and myelin which in turn interferes mitochondrial elec-
tron transport chain and translocates apoptosis inducing 
factor [56]. Thereby, oxidative stress may play a vital role 
in damaging axons via disrupting mitochondrial func-
tion. As a result, energy production will be dropped, pro-
tein and lipid would be oxidized, microtubule would be 
degraded, and axonal transport will be interrupted [57]. 
A recent study reports that axonal damage could be elic-
ited by LPS-mediated microglia activation as well as by 
H2O2-promoted oxidative stress [58].
Prenatal LPS-exposure may lead to the brain damage 
due to the production of toxic free radicals (.OH) [59], 
and an increased level of superoxide anion (O2−) in the 
liver [60]. Free radicals react with the important biologi-
cal substrates, including DNA, proteins, and lipids, which 
interrupt cell function and may lead to cell death. It has 
been reported that LPS induces the activation of micro-
glia [61], reactive astrocyte [62], apoptosis of oligoden-
drocyte precursors which produces superoxide anion 
(O2−), and NO and contributes in neurodegeneration 
[63]. Moreover, LPS treatment triggered the production 
of ROS which in turn causes neuronal cell death in cor-
tex and hippocampus [64, 65] and loss of dopaminergic 
neurons in the striatum [66]. ROS causes cellular dam-
age including lipid peroxidation, interrupts the fluid-
ity of membrane. Our result showed an increased MDA 
level in the prenatal LPS-exposed offspring brain and 
liver, which is consistent with the previous study [67].
The level of glutathione was dropped in the prenatal LPS-
exposed offspring. It is possible because of the action of 
glutathione against lipid peroxidation since it is respon-
sible to reduce the level of peroxidized phospholipids and 
cholesterols [68]. Thus, the level of glutathione reserves 
could be depleted during oxidative stress as we observed 
in the prenatal LPS-exposure group.
Despite the LPS-induced oxidative damage, our results 
showed an improvement of oxidative markers after the 
treatment with astaxanthin in the adult lives. This study 
measured the concentration of MDA, NO, APOP, GSH 
and antioxidant enzyme activity (SOD and CAT) in the 
brain and liver). AST reduces prenatal LPS-induced ele-
vated level of MDA, NO, APOP production and restores 
the concentration of GSH in the brain and liver. In-vitro 
studies were conducted to measure the effect of AST on 
LPS-induced oxidative stress in U937 [53] and RAW264.7 
[69] cell line. Restoration of antioxidant enzyme activity 
(SOD and CAT) and inhibition of NO production have 
been shown by astaxanthin in such oxidative stress cell 
line. In addition, astaxanthin is believed to reduce inflam-
matory cytokine by its antioxidant property. It possibly 
inhibits elevated level of pro-inflammatory cytokines 
by blocking NF-kBactivation [69]. Ohgami et  al. (2003) 
investigated the effect of AST on LPS-induced inflam-
mation in in  vitro and in  vivo model. The author dem-
onstrated that AST reduces the elevated NO production 
and prostaglandin E2 (PGE2) and TNF-α level where 
L-NAME was used as a positive control. The authors fur-
ther suggest that reduction of NO production was due to 
the blocking of NOS enzyme activity similar to the NOS 
inhibitor L-NAME [70]. NO level was decreased with 
the treatment of astaxanthin. NO is involved as a neuro-
transmitter in the CNS which plays an important role in 
learning and memory. Previous study suggests that NO 
is released only during training [71]. Role of AST on NO 
(neurotransmitter) can be investigated during learning 
session. Since we did not measure the level of NO during 
training therefore, this result could not explain the effect 
of AST on signal transmission. However, the reduction of 
NO that is related with free radical induction is benefi-
cial since neuroprotection is evident in the hippocampus 
by low level of lipid peroxidation and increased catalase 
activity.
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The AST treatment was given for 6 weeks; from post-
natal day 91 to 132 with the intent to reduce the stress 
level that was enhanced by prenatal LPS exposure in our 
mice model. This timing of AST treatment was ration-
ally decided after reviewing the previous studies demon-
strating neurochemical abnormalities in the adults after 
prenatal LPS administration [72–74]. In control_AST 
group, only astaxanthin was given to the animals that 
were not prenatally LPS-exposed for better comparison 
and to understand the effect of AST on prenatally LPS-
exposed mice. Most of the parameters obtained from the 
behavioral test (except mobile phase duration in the tail 
suspension test) and oxidative stress markers were sig-
nificantly improved in the brain and liver of the control_
AST and LPS_ASTgroup. Only the GSH in the liver was 
not improved by astaxanthin as compared with LPS_
AST group, which may be due to improper handling of 
tissue samples since our previous study as well as several 
other studies demonstrated a positive effect of AST on 
GSH in the liver [49, 75–77]. Newman-keuls post hoc 
test was done to determine the difference between the 
groups.
The result of the present study showed that astaxan-
thin treatment reduces a prominent marker of lipid per-
oxidation (MDA) which is also observed in the ischemic 
brain injury in adult rats [78]. Wu et al. investigated the 
protective effect of astaxanthin on D-galactose induced 
brain aging in rats. The authors demonstrated that asta-
xanthin treatment restored the activity of SOD, and 
increased GSH, which is in agreement with our present 
findings [28]. However, our study has several limitations; 
we were unable to conduct histology, proteomics, deter-
mination of cytokines and neurotransmitter because of 
lack resources and financial support in our lab. In addi-
tion, astaxanthin was given at a single-dose (2  mg/kg) 
for 6-weeks. Higher or lower dose of astaxanthin could 
be given to investigate the pharmacological profile of this 
antioxidant in animal model. Future study may include 
the determination of the aforesaid compounds to drill 
down more on the activity of astaxanthin on such prena-
tal maternal immune activated postnatal behavioral defi-
cits model.
Nevertheless, the present study is novel in many 
respects. This study first addresses the effect of astaxan-
thinon the prenatal LPS-exposed behavioral disorder in 
the adult offspring in in vivo model. This study focused 
on the determination of six oxidative markers. The results 
of this study open a new avenue to explore the molecular 
mechanism of antioxidant (AST) in developing behavio-
ral disorders. A further study with co-administration of 
astaxanthin and LPS in the prenatal stage to observe the 
protective effect of astaxanthin in the postnatal stage can 
be initiated.
Conclusions
Prenatally LPS-challenged mice developed behavioral 
deficits such as depressive and anxiety like symptoms 
in the adult lives. However, treatment with a potential 
carotenoid antioxidant astaxanthin in the adult life for 
a period of 6  weeks showed a significant improvement 
in the behavioral disorders. We report that astaxan-
thin treatment possibly benefit depressive and anxiety 
episodes by reducing oxidative stress. This study thus 
predicts the potential of astaxanthin in the treatment 
of neuro-psychiatric disease, but future study should 
be conducted to explore underpinning mechanisms to 
ensure the findings.
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